Expert Interview
A third look: Discussing the potential of JAK inhibition in dermatomyositis, with a focus on brepocitinib from Roivant.
Ticker(s): ROIVInstitution: University of Pittsburgh
- Professor of Medicine, rheumatology and Co-Director, UPMC Myositis Center
- Research and clinical areas of interest are clinical and translational research in inflammatory muscle diseases (myositis) and associated interstitial lung disease.
- He is currently the principal investigator or member of the steering committee for several international phase 2/3 clinical trials in the area of myositis and associated ILD
how many DM patients do you manage?
Added By: wilson_adminHow are they currently treated?
Added By: wilson_adminWhat would you need to see for brepocitinib to supplant the current standard of care?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
